Joseph C. Murray, MD, PhD, discusses the safety profiles of encorafenib/binimetinib and dabrafenib/trametinib in patients with BRAF V600E–mutant NSCLC.
Joseph Christopher Murray, MD, PhD
Advertisement
Joseph C. Murray, MD, PhD, is an assistant professor of Oncology, co-director of the Lung Cancer Precision Medicine Center of Excellence, and director of the Upper Aerodigestive Cancer Division Immunotherapy Database at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland.
Articles by Joseph Christopher Murray, MD, PhD
Joseph Christopher Murray, MD, PhD, discusses the investigation of peripheral myeloid cells as prognostic markers in patients with non–small cell lung cancer treated with cemiplimab.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5